The emergency use authorization (EUA) given to Sinovac Biotech’s COVID-19 vaccine was “half-baked,” House Minority Leader and Abang Lingkod Party-list Rep. Joseph Stephen Paduano said Tuesday after the Food and Drug Administration (FDA) did not recommend the Chinese vaccine to medical frontliners.
Paduano said the non-recommendation of Sinovac’s COVID-19 vaccine to medical frontliners despite having an EUA cast doubts on its effectiveness, calling the matter a case of self-contradiction.
“This development only indicated that the EUA issued to Sinovac was half-baked,” Paduano said in a statement.
“It’s very complicated because according to FDA director-general Eric Domingo, the vaccine is 91% effective in Turkey, 65.3% in Indonesia but it registered only 50.4% efficacy among medical frontliners in Brazil,” Paduano said.
FDA Director-General Eric Domingo has bared that human trials of the Sinovac vaccine in Brazil, which had health workers as participants, showed that it is not the best vaccine choice for medical frontliners.